Pfizer/Inhale Therapeutic Look To Exubera Inhaled Insulin NDA Filing In 2001
This article was originally published in The Gray Sheet
Executive Summary
Pfizer says it will file a new drug application (NDA) for Inhale Therapeutic Systems' insulin inhaler by year-end, after completion of a multi-center, Phase III trial testing the product in type 1 and type 2 diabetics.